| Authors: |
He MX; Harvard Graduate Program in Biophysics, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Cuoco MS; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Crowdis J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Bosma-Moody A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, MA, USA., Bi K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Kanodia A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Su MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ku SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garcia MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sweet AR; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Rodman C; Broad Institute of Harvard and MIT, Cambridge, MA, USA., DelloStritto L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Silver R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Steinharter J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shah P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Izar B; Columbia Center for Translational Immunology, New York, NY, USA.; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA., Walk NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Burke KP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA., Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tewari AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Camp SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vokes NI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Thoracic/Head and Neck Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Salari K; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Urology, Massachusetts General Hospital, Boston, MA, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vigneau S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Fong L; Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA., Russo JW; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Yuan X; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Balk SP; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rozenblatt-Rosen O; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Regev A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Biology, Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Genentech, South San Francisco, CA, USA., Rotem A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA.; AstraZeneca, Waltham, MA, USA., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu. |
